Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines. Specifically, the Company reported earnings per share (“EPS”) of $0.12, missing EPS expectations of $0.29 by nearly 60%. TransMedics also reported revenue of $108.8 million, falling short of analysts’ $115 million estimate.
Following this news, TransMedics stock dropped over 24% in after-hours trading.